Flamel Technologies S.A. (ADR)  

(Public, NASDAQ:FLML)   Watch this stock  
Find more results for flml
11.26
+0.66 (6.23%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.26 - 11.58
52 week 4.10 - 14.95
Open 10.50
Vol / Avg. 310,600.00/338,275.00
Mkt cap 286.18M
P/E     -
Div/yield     -
EPS -1.53
Shares 25.42M
Beta 0.56
Inst. own 40%
Jun 16, 2014
Flamel Technologies Annual Shareholder Meeting (Estimated) Add to calendar
Jun 2, 2014
Flamel Technologies at Jefferies Global Healthcare Conference Add to calendar
May 5, 2014
Q1 2014 Flamel Technologies Earnings Release (Estimated) Add to calendar
Apr 7, 2014
Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial With Micropump Sodium Oxybate Conference Call
Mar 25, 2014
Q4 2013 Flamel Technologies Earnings Conference Call
Mar 25, 2014
Q4 2013 Flamel Technologies Earnings Release
Feb 11, 2014
Flamel Technologies SA Extraordinary Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin -114.08% -12.37%
Operating margin -121.80% -32.04%
EBITD margin - -64.53%
Return on average assets -21.75% -3.46%
Return on average equity - -10.71%
Employees 264 -
CDP Score - -

Address

33, avenue du Dr. Georges Levy, Venissieux Cedex, PARC CLUB DU MOULIN A VENT
VENISSIEUX, 69693
France
+33-4-72783434 (Phone)
+33-4-72783435 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Flamel Technologies SA has a pipeline of niche specialty pharmaceutical products. The Company�s drug delivery platforms are focused on developing safer, more efficacious formulations of drugs to address unmet medical needs. Its pipeline includes biological and chemical drugs formulated with its Medusa and Micropump (and its applications to the development of liquid formulations, which is LiquiTime and of abuse-deterrent formulations Trigger Lock) drug delivery platforms. It has collaborations with a number of pharmaceutical and biotechnology companies, including GlaxoSmithKline (Coreg CR, carvedilol phosphate). Its Medusa is based on a hydrophilic biodegradable polyglutamate chain grafted with hydrophobic Vitamin E. The Company�s LiquiTime allows the development of oral controlled release liquid formulations of drugs for patients who have difficulty swallowing tablets or capsules, such as children and the elderly.

Officers and directors

Stephen H. Willard Non-Executive Chairman of the Board
Bio & Compensation  - Reuters
Michael S. Anderson Chief Executive Officer, Director
Bio & Compensation  - Reuters
Sian Crouzet Principal Financial Officer
Bio & Compensation  - Reuters
Rafael Jorda Chief Operating Officer, Executive Vice President
Bio & Compensation  - Reuters
Steven A. Lisi Senior Vice President - Business and Corporate Development
Bio & Compensation  - Reuters
Gregg Stetsko Ph.D. Vice President - Research & Development
Bio & Compensation  - Reuters
Catherine Castan Director - Micropump Platform (Oral Drugs) and Intellectual Property
Bio & Compensation  - Reuters
Christian Kalita Pharmacist and Director - Quality Assurance and Regulatory Affairs
Bio & Compensation  - Reuters
Elie Vannier Director
Age: 63
Bio & Compensation  - Reuters
Catherine Brechignac PH.D Independent Director
Bio & Compensation  - Reuters